CN104971102A - Drug composition for treating diabetic nephropathy, preparation method and uses thereof - Google Patents
Drug composition for treating diabetic nephropathy, preparation method and uses thereof Download PDFInfo
- Publication number
- CN104971102A CN104971102A CN201510151713.2A CN201510151713A CN104971102A CN 104971102 A CN104971102 A CN 104971102A CN 201510151713 A CN201510151713 A CN 201510151713A CN 104971102 A CN104971102 A CN 104971102A
- Authority
- CN
- China
- Prior art keywords
- parts
- crude drug
- diabetic nephropathy
- pharmaceutical composition
- semen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 73
- 229940079593 drug Drugs 0.000 title claims abstract description 62
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims abstract description 39
- 208000033679 diabetic kidney disease Diseases 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 28
- 210000000582 semen Anatomy 0.000 claims description 76
- 239000009636 Huang Qi Substances 0.000 claims description 49
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 241000600871 Euryale <brittle star> Species 0.000 claims description 27
- 239000008187 granular material Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 11
- 238000009835 boiling Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 206010001580 Albuminuria Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 230000002485 urinary effect Effects 0.000 abstract description 5
- 102000009027 Albumins Human genes 0.000 abstract description 4
- 108010088751 Albumins Proteins 0.000 abstract description 4
- 229940109239 creatinine Drugs 0.000 abstract description 4
- 230000029142 excretion Effects 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 210000002700 urine Anatomy 0.000 abstract description 4
- 206010022530 Intercapillary glomerulosclerosis Diseases 0.000 abstract description 3
- 230000003111 delayed effect Effects 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000214021 Astragalus complanatus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 241000037740 Coptis chinensis Species 0.000 abstract 1
- 244000268590 Euryale ferox Species 0.000 abstract 1
- 235000000661 Rosa laevigata Nutrition 0.000 abstract 1
- 241001278833 Rosa laevigata Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000002131 composite material Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 206010054805 Macroangiopathy Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 206010061989 glomerulosclerosis Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000216 vascular lesion Toxicity 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010038372 Renal arteriosclerosis Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 208000004670 arteriolosclerosis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of medicine, and particularly relates to a drug composition for treating diabetic nephropathy, a preparation method and uses thereof. The technical problem solved by the present invention is to provide a completely-new drug composition for treating diabetic nephropathy. According to the drug composition of the present invention, caulis sinomenii, astragalus complanatus, milkvetch root and coptis chinensis are adopted as main bulk drugs to achieve the diabetic nephropathy treating purpose; and rosa laevigata michx and euryale ferox can further be added so as to further improve the treatment effect of the drug composition. According to the present invention, the most typical symptom of the diabetic nephropathy is nodular glomerulosclerosis and mainly the excretion amount of the urinary albumin is adopted as the diagnostic indicator, and after patients take the drug composition, the proteinuria excretion is significantly reduced, the 24 h urine total protein level and the urinary albumin excretion rate are reduced, the urinary albumin/creatinine ratio is reduced, the serum creatinine level is lowered, the life quality of patients is significantly improved, and the progress of the diabetic nephropathy disease is delayed.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to pharmaceutical composition for the treatment of diabetic nephropathy and its production and use.
Background technology
Diabetic nephropathy is one of Diabetic microvascular complication, is the important death cause of diabetics.The diabetes nephropathy of broad sense comprises infection and vascular lesions.Infection has pyelonephritis and necrosis of renal papillae.Vascular lesions divides blood capillary and macroangiopathy, and macroangiopathy comprises renal arteriosclerosis (involving trunk and branch) and renal arteriolosclerosis (involving people's ball and efferent glomerular arteriole).Microangiopathies refers to glomerular sclerosis, and point nodositas, exudative and diffusivity three kinds, three can merge existence separately, and in above-mentioned change, most typical is nodular glomerulosclerosis.The diabetic nephropathy that we say usually is glomerular sclerosis.Diabetic nephropathy there is no specific short.Treatment principle is: 1. strict glycemic control, makes blood glucose close to normal level as far as possible, prevents and delays diabetic nephropathy occurs; 2. the speed of renal hypofunction is delayed; 3. dialysis treatment and renal transplantation.
The document utilizing Chinese medical theory to treat diabetic nephropathy can be seen in " summary of experience of Li Xiaojuan Experience in Treating diabetic nephropathy " [Han Yunping, Liaoning medical pharmaceutical university, master thesis, 20090401] " a flat Experience in Treating diabetic nephropathy experience " [mountain peak, Liaoning medical pharmaceutical university, master thesis, 20100401].
The present invention for provide a kind of completely newly, the significant medicine of clear curative effect is used for the treatment of diabetic nephropathy.
Summary of the invention
Technical problem solved by the invention is to provide a kind of brand-new pharmaceutical composition and is used for the treatment of diabetic nephropathy.
Pharmaceutical composition of the present invention is with Caulis Sinomenii, Semen Astragali Complanati, the Radix Astragali, and Rhizoma Coptidis is primary raw material medicine, and reach the object for the treatment of diabetic nephropathy, pharmaceutical composition of the present invention can also add Fructus Rosae Laevigatae, and Semen Euryales is to promote the curative effect of pharmaceutical composition further.
1) pharmaceutical composition of the present invention is with Caulis Sinomenii, Semen Astragali Complanati, the Radix Astragali, when Rhizoma Coptidis is crude drug:
Crude drug weight proportion is as follows: Caulis Sinomenii 10-120 part, Semen Astragali Complanati 10-120 part, Radix Astragali 10-120 part, Rhizoma Coptidis 5-60 part.
Crude drug preferred weight proportioning is as follows: Caulis Sinomenii 10-50 part, Semen Astragali Complanati 10-50 part, Radix Astragali 10-50 part, Rhizoma Coptidis 5-30 part.
Crude drug further preferred weight proportioning is as follows: Caulis Sinomenii 20-40 part, Semen Astragali Complanati 20-40 part, Radix Astragali 20-40 part, Rhizoma Coptidis 5-15 part.
Crude drug most preferably weight proportion is as follows: Caulis Sinomenii 30 parts, Semen Astragali Complanati 30 parts, the Radix Astragali 30 parts, Rhizoma Coptidis 10 parts.
2) pharmaceutical composition of the present invention is with Caulis Sinomenii, Semen Astragali Complanati, the Radix Astragali, Rhizoma Coptidis, Fructus Rosae Laevigatae, when Semen Euryales is crude drug:
Crude drug weight proportion is as follows: Caulis Sinomenii 10-120 part, Semen Astragali Complanati 10-120 part, Radix Astragali 10-120 part, Rhizoma Coptidis 5-60 part, Fructus Rosae Laevigatae 5-60 part, Semen Euryales 5-60 part.
Crude drug preferred weight proportioning is as follows: Caulis Sinomenii 10-50 part, Semen Astragali Complanati 10-50 part, Radix Astragali 10-50 part, Rhizoma Coptidis 5-30 part, Fructus Rosae Laevigatae 5-30 part, Semen Euryales 5-30 part.
Crude drug further preferred weight proportioning is as follows: Caulis Sinomenii 20-40 part, Semen Astragali Complanati 20-40 part, Radix Astragali 20-40 part, Rhizoma Coptidis 5-15 part, Fructus Rosae Laevigatae 10-20 part, Semen Euryales 10-20 part.
Crude drug most preferably weight proportion is as follows: Caulis Sinomenii 30 parts, Semen Astragali Complanati 30 parts, the Radix Astragali 30 parts, Rhizoma Coptidis 10 parts, Fructus Rosae Laevigatae 15 parts, Semen Euryales 15 parts.
The most typical symptom of diabetic nephropathy is nodular glomerulosclerosis, mainly with urinaryalbumin output how much for diagnosis index.After patient adopts pharmaceutical composition of the present invention, albuminuria output, obviously reduces, and twenty-four-hour urine total protein levels, urinary albumin excretion ratio reduce, urinary albumin-creatinine ratio ratio reduces, serum creatinine level reduces, and patients ' life quality obviously improves, and has delayed the progress of diabetic nephropathy disease.
For the ease of application, can on the basis of crude drug, conventionally or add pharmaceutically acceptable adjuvant and make conventional oral formulations.As powder, capsule, tablet, granule, capsule, oral liquid etc.For the application characteristic of medicine of the present invention, additionally provide the preparation method of this pharmaceutical composition.
As:
Method one: each crude drug is ground into fine powder, mixing powder;
Method two: each crude drug is ground into fine powder, encapsulated capsule;
Method three: each crude drug is ground into fine powder, tabletting tablet;
Method four: after each crude drug water boiling and extraction, concentrated extracting solution makes granule, granule;
Method five: after each crude drug water boiling and extraction, concentrated extracting solution makes granule, encapsulated capsule;
Method six: after each crude drug water boiling and extraction, concentrated extracting solution makes granule, tabletting tablet;
Method seven: after each crude drug water boiling and extraction, make oral liquid.
Application said method all can realize the object for the treatment of diabetes, but because of the convenience of application and the easy of preparation, inventor is made into granule more and uses.
To sum up, applying medicine composite for curing diabetes provided by the invention has clear and definite effect, stable curative effect, has no side effect, controlled.
Detailed description of the invention
Illustrate below by way of specific description of embodiments of the present invention but do not limit the present invention.
The pharmaceutical composition that the present invention is used for the treatment of diabetic nephropathy is made up of the crude drug of following weight proportion:
1) pharmaceutical composition of the present invention is with Caulis Sinomenii, Semen Astragali Complanati, the Radix Astragali, when Rhizoma Coptidis is crude drug:
Crude drug weight proportion is as follows: Caulis Sinomenii 10-120 part, Semen Astragali Complanati 10-120 part, Radix Astragali 10-120 part, Rhizoma Coptidis 5-60 part.
Crude drug preferred weight proportioning is as follows: Caulis Sinomenii 10-50 part, Semen Astragali Complanati 10-50 part, Radix Astragali 10-50 part, Rhizoma Coptidis 5-30 part.
Crude drug further preferred weight proportioning is as follows: Caulis Sinomenii 20-40 part, Semen Astragali Complanati 20-40 part, Radix Astragali 20-40 part, Rhizoma Coptidis 5-15 part.
Crude drug most preferably weight proportion is as follows: Caulis Sinomenii 30 parts, Semen Astragali Complanati 30 parts, the Radix Astragali 30 parts, Rhizoma Coptidis 10 parts.
2) pharmaceutical composition of the present invention is with Caulis Sinomenii, Semen Astragali Complanati, the Radix Astragali, Rhizoma Coptidis, Fructus Rosae Laevigatae, when Semen Euryales is crude drug:
Crude drug weight proportion is as follows: Caulis Sinomenii 10-120 part, Semen Astragali Complanati 10-120 part, Radix Astragali 10-120 part, Rhizoma Coptidis 5-60 part, Fructus Rosae Laevigatae 5-60 part, Semen Euryales 5-60 part.
Crude drug preferred weight proportioning is as follows: Caulis Sinomenii 10-50 part, Semen Astragali Complanati 10-50 part, Radix Astragali 10-50 part, Rhizoma Coptidis 5-30 part, Fructus Rosae Laevigatae 5-30 part, Semen Euryales 5-30 part.
Crude drug further preferred weight proportioning is as follows: Caulis Sinomenii 20-40 part, Semen Astragali Complanati 20-40 part, Radix Astragali 20-40 part, Rhizoma Coptidis 5-15 part, Fructus Rosae Laevigatae 10-20 part, Semen Euryales 10-20 part.
Crude drug most preferably weight proportion is as follows: Caulis Sinomenii 30 parts, Semen Astragali Complanati 30 parts, the Radix Astragali 30 parts, Rhizoma Coptidis 10 parts, Fructus Rosae Laevigatae 15 parts, Semen Euryales 15 parts.
Inventor, when nearly clinical practice in 2 years, adjusts the consumption of crude drug within the scope of following weight proportion, all can realize treatment diabetic nephropathy object:
With Caulis Sinomenii, Semen Astragali Complanati, the Radix Astragali, when Rhizoma Coptidis is crude drug, crude drug most preferably weight proportion is as follows:
Caulis Sinomenii 30 parts, Semen Astragali Complanati 30 parts, the Radix Astragali 30 parts, Rhizoma Coptidis 10 parts.
With Caulis Sinomenii, Semen Astragali Complanati, the Radix Astragali, Rhizoma Coptidis, Fructus Rosae Laevigatae, when Semen Euryales is crude drug, crude drug most preferably weight proportion is as follows:
Caulis Sinomenii 30 parts, Semen Astragali Complanati 30 parts, the Radix Astragali 30 parts, Rhizoma Coptidis 10 parts, Fructus Rosae Laevigatae 15 parts, Semen Euryales 15 parts.
For the ease of application, on the basis of crude drug, pharmaceutically acceptable adjuvant can be added and makes conventional oral formulations.As powder, capsule, tablet, granule, capsule, oral liquid etc.
The beneficial effect of pharmaceutical composition of the present invention is proved below by way of clinical statistics.
It is clinical that inventor adopts pharmaceutical composition of the present invention to be applied to, and gets different amounts proportioning raw material for different indication, makes following dosage form and apply,
Prescription: during practical application, crude drug can adopt following weight proportion:
1) Caulis Sinomenii 120 parts, Semen Astragali Complanati 10 parts, the Radix Astragali 120 parts, Rhizoma Coptidis 60 parts.
2) Caulis Sinomenii 60 parts, Semen Astragali Complanati 120 parts, the Radix Astragali 10 parts, Rhizoma Coptidis 5 parts.
3) Caulis Sinomenii 30 parts, Semen Astragali Complanati 10 parts, the Radix Astragali 10 parts, Rhizoma Coptidis 5 parts.
4) Caulis Sinomenii 40 parts, Semen Astragali Complanati 50 parts, the Radix Astragali 10 parts, Rhizoma Coptidis 5 parts.
5) Caulis Sinomenii 30 parts, Semen Astragali Complanati 20 parts, the Radix Astragali 50 parts, Rhizoma Coptidis 30 parts.
6) Caulis Sinomenii 10 parts, Semen Astragali Complanati 40 parts, the Radix Astragali 30 parts, Rhizoma Coptidis 10 parts.
7) Caulis Sinomenii 20 parts, Semen Astragali Complanati 120 parts, the Radix Astragali 10 parts, Rhizoma Coptidis 5 parts, Fructus Rosae Laevigatae 5 parts, Semen Euryales 5 parts.
8) Caulis Sinomenii 120 parts, Semen Astragali Complanati 10 parts, the Radix Astragali 10 parts, Rhizoma Coptidis 15 parts, Fructus Rosae Laevigatae 10 parts, Semen Euryales 10 parts.
9) Caulis Sinomenii 30 parts, Semen Astragali Complanati 10 parts, the Radix Astragali 120 parts, Rhizoma Coptidis 60 parts, Fructus Rosae Laevigatae 60 parts, Semen Euryales 60 parts.
10) Caulis Sinomenii 60 parts, Semen Astragali Complanati 10 parts, the Radix Astragali 10 parts, Rhizoma Coptidis 5 parts, Fructus Rosae Laevigatae 5 parts, Semen Euryales 5 parts.
11) Caulis Sinomenii 10 parts, Semen Astragali Complanati 40 parts, the Radix Astragali 40 parts, Rhizoma Coptidis 15 parts, Fructus Rosae Laevigatae 20 parts, Semen Euryales 20 parts.
12) Caulis Sinomenii 50 parts, Semen Astragali Complanati 10 parts, the Radix Astragali 50 parts, Rhizoma Coptidis 30 parts, Fructus Rosae Laevigatae 30 parts, Semen Euryales 30 parts
13) Caulis Sinomenii 30 parts, Semen Astragali Complanati 30 parts, the Radix Astragali 30 parts, Rhizoma Coptidis 10 parts, Fructus Rosae Laevigatae 15 parts, Semen Euryales 15 parts.
During clinical practice, inventor be made into granule application, adopt above-mentioned different material medicine proportion relation to prepare granule respectively, preparation method is as follows: after each crude drug water boiling and extraction, concentrated extracting solution makes granule, granule.
Pharmaceutical composition of the present invention: take dosage on 2nd: Caulis Sinomenii 30g, Radix Astragali 30g, Rhizoma Coptidis 10g, Semen Astragali Complanati 30g, Fructus Rosae Laevigatae 15g, Semen Euryales 15g; One day three times.
Control drug: day takes dosage: Radix Astragali 30g, Rhizoma Coptidis 10g, Semen Astragali Complanati 30g, Fructus Rosae Laevigatae 15g, Semen Euryales 15g; One day three times.
Inventor applies the 13rd group of medicine composite for curing diabetic nephropathy.Nearly 2 years treatment more than 50 people, with reference to nephropathy branch of China Association of Traditional Chinese Medicine " diabetic nephropathy diagnosis, differentiation of symptoms and signs for classification of syndrome and efficacy assessment standard " therapeutic effect of grading in 2006.About 2 weeks pharmaceutical composition onset times of the present invention, healing time about 8 weeks, recurrence about 5%.
The non-clinical statistical data applying pharmaceutical composition of the present invention and control drug is as follows:
Note:
Transference cure: represent that clinical symptoms disappears substantially, twenty-four-hour urine protein quantification <30mg/24h.
Symptom alleviates: represent that clinical symptoms significantly alleviates, the quantitative <300mg/24h of 30mg/24h<24 hours urine protein.
Total effective rate alleviates sum in transference cure and symptom.
Apply medicine composite for curing diabetic nephropathy patient of the present invention, the albuminuria discharge capacity of patient obviously reduces, thus can slow down the process of diabetic nephropathy disease progression.
To sum up, pharmaceutical composition of the present invention is through clinical statistics observation for many years, finally determine that Caulis Sinomenii, Semen Astragali Complanati, Rhizoma Coptidis, the Radix Astragali are primary raw material medicine after screening prescription, and add Fructus Rosae Laevigatae, the further consolidate curative effect of Semen Euryales, treatment diabetic nephropathy best results, for clinical treatment diabetes provide a kind of selection completely newly.
Claims (10)
1. treat the pharmaceutical composition of diabetic nephropathy, it is characterized in that: crude drug weight proportion is as follows:
Caulis Sinomenii 10-120 part, Semen Astragali Complanati 10-120 part, Radix Astragali 10-120 part, Rhizoma Coptidis 5-60 part.
2. the pharmaceutical composition being used for the treatment of diabetic nephropathy according to claim 1, is characterized in that: crude drug weight proportion is as follows:
Caulis Sinomenii 10-50 part, Semen Astragali Complanati 10-50 part, Radix Astragali 10-50 part, Rhizoma Coptidis 5-30 part.
3. the pharmaceutical composition being used for the treatment of diabetic nephropathy according to claim 2, is characterized in that: crude drug weight proportion is as follows:
Caulis Sinomenii 20-40 part, Semen Astragali Complanati 20-40 part, Radix Astragali 20-40 part, Rhizoma Coptidis 5-15 part;
Preferably, crude drug weight proportion is as follows:
Caulis Sinomenii 30 parts, Semen Astragali Complanati 30 parts, the Radix Astragali 30 parts, Rhizoma Coptidis 10 parts.
4. treat the pharmaceutical composition of diabetic nephropathy, it is characterized in that: crude drug weight proportion is as follows:
Caulis Sinomenii 10-120 part, Semen Astragali Complanati 10-120 part, Radix Astragali 10-120 part, Rhizoma Coptidis 5-60 part, Fructus Rosae Laevigatae 5-60 part, Semen Euryales 5-60 part.
5. according to the pharmaceutical composition being used for the treatment of diabetic nephropathy that claim 4 is stated, it is characterized in that: crude drug weight proportion is as follows:
Caulis Sinomenii 10-50 part, Semen Astragali Complanati 10-50 part, Radix Astragali 10-50 part, Rhizoma Coptidis 5-30 part, Fructus Rosae Laevigatae 5-30 part, Semen Euryales 5-30 part.
6. according to the pharmaceutical composition being used for the treatment of diabetic nephropathy that claim 5 is stated, it is characterized in that: crude drug weight proportion is as follows:
Caulis Sinomenii 20-40 part, Semen Astragali Complanati 20-40 part, Radix Astragali 20-40 part, Rhizoma Coptidis 5-15 part, Fructus Rosae Laevigatae 10-20 part, Semen Euryales 10-20 part;
Preferably, crude drug weight proportion is as follows:
Caulis Sinomenii 30 parts, Semen Astragali Complanati 30 parts, the Radix Astragali 30 parts, Rhizoma Coptidis 10 parts, Fructus Rosae Laevigatae 15 parts, Semen Euryales 15 parts.
7. the pharmaceutical composition being used for the treatment of diabetic nephropathy according to any one of claim 1-6, is characterized in that: described pharmaceutical composition is on the basis of crude drug, conventionally makes oral formulations; Or add pharmaceutically acceptable adjuvant and make conventional oral formulations.
8. the pharmaceutical composition being used for the treatment of diabetic nephropathy according to claim 7, is characterized in that: described oral formulations is powder, tablet, granule, capsule or oral liquid.
9. the preparation method being used for the treatment of the pharmaceutical composition of diabetic nephropathy described in any one of claim 1-6, is characterized in that:
Method one: each crude drug is ground into fine powder, mixing powder; Or
Method two: each crude drug is ground into fine powder, encapsulated capsule; Or
Method three: each crude drug is ground into fine powder, tabletting tablet; Or
Method four: after each crude drug water boiling and extraction, concentrated extracting solution makes granule, granule; Or
Method five: after each crude drug water boiling and extraction, concentrated extracting solution makes granule, encapsulated capsule; Or
Method six: after each crude drug water boiling and extraction, concentrated extracting solution makes granule, tabletting tablet; Or
Method seven: after each crude drug water boiling and extraction, make oral liquid.
10. the pharmaceutical composition described in any one of claim 1-6 reduces the purposes in the medicine of albuminuria output in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510151713.2A CN104971102B (en) | 2014-04-03 | 2015-04-01 | The pharmaceutical composition and its preparation method and application for treating diabetic nephropathy |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410134086 | 2014-04-03 | ||
| CN2014101340867 | 2014-04-03 | ||
| CN201510151713.2A CN104971102B (en) | 2014-04-03 | 2015-04-01 | The pharmaceutical composition and its preparation method and application for treating diabetic nephropathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104971102A true CN104971102A (en) | 2015-10-14 |
| CN104971102B CN104971102B (en) | 2018-11-23 |
Family
ID=54268423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510151713.2A Expired - Fee Related CN104971102B (en) | 2014-04-03 | 2015-04-01 | The pharmaceutical composition and its preparation method and application for treating diabetic nephropathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104971102B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105194458A (en) * | 2015-10-21 | 2015-12-30 | 彭书磊 | Traditional Chinese medicine for treating diabetic nephropathy |
| CN105998854A (en) * | 2016-07-24 | 2016-10-12 | 刘咏梅 | Medicine for treating diabetic nephropathy and preparation method |
| CN108114032A (en) * | 2017-01-24 | 2018-06-05 | 青海春天药用资源科技利用有限公司 | There is the pharmaceutical composition of invigorating the blood |
| CN110772607A (en) * | 2019-10-21 | 2020-02-11 | 南方医科大学 | Traditional Chinese medicine composition for improving diabetic nephropathy and preparation thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080118584A1 (en) * | 2006-11-16 | 2008-05-22 | Jose Angel Olalde Rangel | Renal Synergistic Phyto-Nutraceutical Composition |
| CN102228536A (en) * | 2011-06-09 | 2011-11-02 | 首都医科大学 | Chinese herbal extract for treating diabetic nephropathy and preparation method thereof |
-
2015
- 2015-04-01 CN CN201510151713.2A patent/CN104971102B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080118584A1 (en) * | 2006-11-16 | 2008-05-22 | Jose Angel Olalde Rangel | Renal Synergistic Phyto-Nutraceutical Composition |
| CN102228536A (en) * | 2011-06-09 | 2011-11-02 | 首都医科大学 | Chinese herbal extract for treating diabetic nephropathy and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 张李兴等: "活血化瘀法治疗糖尿病肾病经验", 《吉林中医药》 * |
| 徐蓉娟工作室: "《徐蓉娟学术经验擷英》", 31 July 2010 * |
| 罗来敏等: "正清风痛宁治疗糖尿病肾病的疗效及对血浆内皮素水平的影响", 《江西医学院学报》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105194458A (en) * | 2015-10-21 | 2015-12-30 | 彭书磊 | Traditional Chinese medicine for treating diabetic nephropathy |
| CN105194458B (en) * | 2015-10-21 | 2019-12-17 | 薛武 | Traditional Chinese medicine for treating diabetic nephropathy |
| CN105998854A (en) * | 2016-07-24 | 2016-10-12 | 刘咏梅 | Medicine for treating diabetic nephropathy and preparation method |
| CN108114032A (en) * | 2017-01-24 | 2018-06-05 | 青海春天药用资源科技利用有限公司 | There is the pharmaceutical composition of invigorating the blood |
| CN110772607A (en) * | 2019-10-21 | 2020-02-11 | 南方医科大学 | Traditional Chinese medicine composition for improving diabetic nephropathy and preparation thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104971102B (en) | 2018-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102343023B (en) | Medicinal composition and preparation method and application thereof | |
| CN102671137B (en) | Medicine composition for treating diabetic nephropathy and preparation method of medicine composition | |
| CN103040960A (en) | Traditional Chinese medicine formula for treating high blood pressure | |
| CN104971102A (en) | Drug composition for treating diabetic nephropathy, preparation method and uses thereof | |
| CN103751545B (en) | A kind of Chinese medicine preparation treating type of deficiency of both QI and YIN IgA nephropathy | |
| CN102120020B (en) | Medicinal composition for treating hyperplastic diseases of breast and hysteromyoma and preparation method thereof | |
| CN102886033B (en) | Traditional Chinese medicine preparation for promoting postpartum recovery of parturients and shortening lochial time | |
| CN101417039B (en) | Medicine wine for treating gout | |
| CN102716276B (en) | Medicine for oral use for treating diabetes | |
| CN104258051B (en) | Traditional Chinese medicine composition for treating gouty arthritis, and preparation method thereof | |
| CN102988892B (en) | Medicament for treating hysteromyoma and ovarian cysts | |
| CN104524247A (en) | Pharmaceutical composition for treating migraine and application thereof | |
| CN103800736B (en) | A kind of pharmaceutical composition treating hypertensive nephropathy and application thereof | |
| CN104971101A (en) | Drug composition for treating diabetic nephropathy, preparation method and uses thereof | |
| CN105311470A (en) | Application of pharmaceutical composition containing folium artemisiae argyi in preparing medicine for treating diabetic nephropathy | |
| CN105663439A (en) | Pharmaceutical composition for preventing and treating diabetes and preparation method thereof | |
| CN104225074A (en) | Traditional Chinese medicinal pill for treating diabetes | |
| CN108653559A (en) | A kind of hypoglycemic composition and its application | |
| CN101244127B (en) | Medicament for treating vascular dementia | |
| CN102091271A (en) | Medicine for treating hyperplasia of mammary glands and preparation method thereof | |
| CN104127475A (en) | New use of Flatstem Milkvetch Seed | |
| CN103041288A (en) | Chinese medicinal composition for treating diabetic fatty liver and preparation process thereof | |
| CN110237179A (en) | A kind of Chinese medicine composition and its preparation method and application | |
| CN104758503B (en) | It is a kind of promote union composition and its decocting liquid preparation method | |
| CN104998154A (en) | Traditional Chinese medicine compound treating cervical spondylosis and acute pharyngitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181123 |